%0 Journal Article %A Shoa L. Clarke %A Catherine Tcheandjieu %A Austin Hilliard %A Kyung Min Lee %A Julie Lynch %A Kyong-Mi Chang %A Donald Miller %A VA Million Veteran Program %A Joshua W. Knowles %A Christopher O’Donnell %A Phil Tsao %A Daniel J. Rader %A Peter W. Wilson %A Yan V. Sun %A Michael Gaziano %A Themistocles L. Assimes %T Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Historical Cholesterol Exposure %D 2020 %R 10.1101/2020.11.12.20230904 %J medRxiv %P 2020.11.12.20230904 %X Aims Familial hypercholesterolemia (FH) genetic variants confer risk for coronary artery disease (CAD) even after adjusting for low-density lipoprotein cholesterol (LDL-C) levels, using a single measurement. This study evaluated whether multiple historical measures of LDL-C observed in the electronic health record (EHR) can account for the risk associated with FH variants.Methods and Results We analyzed 418,790 participants in the Million Veteran Program with EHR data spanning up to 15 years prior to and 7 years after enrollment, including ∼6.3 million LDL-C measurements. FH variants in LDLR, APOB, and PCSK9 were identified using a custom genotype array. We implemented a nested case-control design, using incidence density sampling to match etiologic exposure windows and measure CAD risk while adjusting for LDL-C exposure. In a cohort of 23,091 primarily prevalent cases and 230,910 matched controls, FH variants conferred increased risk for CAD (odds ratio: 1.53; 95% confidence interval: 1.24 to 1.89; p: 7.8×10−5). Adjusting for mean LDL-C exposure prior to the index date attenuated this risk more than adjusting for a single measurement, but significant risk remained (odds ratio: 1.33; 95% confidence interval: 1.08 to 1.64; p = 8.4×10−3). The pattern was also apparent in stratified analyses by sex and ancestry, and we found evidence of an interaction between sex and FH carrier status.Conclusion The risk associated with FH variants cannot be fully captured by the LDL-C data available in the EHR, even when considering multiple LDL-C measurements spanning more than a decade.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grants 2I01BX003362 and 1I01BX004821. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The VA Central Institutional Review Board approved the MVP study protocol in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual data cannot be shared publicly according to the Data Access Policy of the Million Veteran Program in the VA Office of R&D in Veterans Health Administration. Requests for data access be submitted to Dr. Jennifer Moser PhD (Jennifer.Moser{at}va.gov) at the Genomic Medicine & Million Veteran Program in the VA Office of R&D. %U https://www.medrxiv.org/content/medrxiv/early/2020/11/16/2020.11.12.20230904.full.pdf